VolitionRx Ltd. Q1 2025 10-Q: Assets $175M, Equity $96.1M

Ticker: VNRX · Form: 10-Q · Filed: May 15, 2025 · CIK: 93314

Sentiment: neutral

Topics: financials, 10-Q, subsequent-events

TL;DR

VNRX Q1 2025: $175M assets, $96.1M equity. New plans adopted.

AI Summary

VolitionRx Ltd. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $175 million and total liabilities of $100.7 million, resulting in total equity of $96.1 million. The filing also details several subsequent events, including the establishment of the TwentyFifteen Plan and the TwentyTwentyFour Plan, with specific dates of adoption and amendments.

Why It Matters

This filing provides a snapshot of VolitionRx's financial health and significant corporate actions, offering insights into its operational status and future plans.

Risk Assessment

Risk Level: medium — The company's financial figures and subsequent events indicate ongoing operational and strategic activities that carry inherent business risks.

Key Numbers

Key Players & Entities

FAQ

What were VolitionRx Ltd.'s total assets as of March 31, 2025?

VolitionRx Ltd.'s total assets were $175,000,000 as of March 31, 2025.

What were the total liabilities for VolitionRx Ltd. at the end of the first quarter of 2025?

The total liabilities for VolitionRx Ltd. were $100,746,467 for the period ending March 31, 2025.

What was the total equity reported by VolitionRx Ltd. in its Q1 2025 10-Q filing?

VolitionRx Ltd. reported total equity of $96,097,485 in its Q1 2025 10-Q filing.

What subsequent events related to employee plans were mentioned in the filing?

The filing mentions subsequent events related to the 'TwentyFifteen Plan' and the 'TwentyTwentyFour Plan', with various adoption and amendment dates in April and May 2025.

When was the 10-Q filing for VolitionRx Ltd. submitted?

The 10-Q filing for VolitionRx Ltd. was submitted on May 15, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding VOLITIONRX LTD (VNRX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing